Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma.

ABSTRACT: Children with ependymoma (EPN) are cured in less than 50% of cases, with little improvement in outcome over the last several decades. Chemotherapy has not affected survival in EPN, due in part to a lack of preclinical models that has precluded comprehensive drug testing. We recently developed two human EPN cell lines harboring high-risk phenotypes which provided us with an opportunity to execute translational studies. EPN and other pediatric brain tumor cell lines were subject to a large-scale comparative drug screen of FDA-approved oncology drugs for rapid clinical application. The results of this in vitro study were combined with in silico prediction of drug sensitivity to identify EPN-selective compounds, which were validated by dose curve and time course modeling. Mechani

SUBMITTER: Donson AM 

PROVIDER: S-EPMC6125158 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature